The health benefits of “resveratrol” found in red wine and dark chocolate have long been heralded by the holistic community and acknowledged by scientists as well. Now, a new study may offer a breakthrough in effectively understanding and concentrating this life-extending compound.
For a long while, people have reacted to the health benefits of red wine and dark chocolate with a wry smile. After all, it would seem too good to be true that two indulgent consumables, which are certainly not beneficial to one’s health when abused, could at the same time foster good health and life-extending properties when eaten in moderation.
While the holistic and natural supplement sectors have done a good job at marketing resveratrol, the compound associated with red wine and dark chocolate that even scientists agree offers defenses against obesity, diabetes, certain cancers, depression, and other diseases, the exact nature of this compound has remained enough of a mystery to keep researchers from the biotech sector from effectively understanding and concentrating it for medicinal use.
However, a new report in last Friday’s edition of Science points to major discoveries concerning these once-elusive compounds, leading researchers to believe that the “resveratrol” could eventually come to be commercialized and prescribed by the medical community.
An article in the Yakima Herald explains how . . .
Harvard geneticist David Sinclair and his colleagues have been working for more than a decade to uncover a chemical link between resveratrol and a group of enzymes known as sirtuins, which can trigger proteins that rejuvenate cells. The new results will help achieve a “more rational design” of resveratrol-related drugs, Sinclair said.
The real significance behind Sinclair’s findings are that they in essence put to rest a major argument in the scientific community over whether or not some of the early findings concerning resveratrol were in fact reliable, or otherwise little more than test tube experiments that would never translate into real-life results. In light of the new findings, the science community agrees that there is indeed a remarkable effect from the use of resveratrol, and that it should be able to be easily applied to the life sciences.
This isn’t to say, however, that the commercial biotech industry has ignored experimenting with resveratrol up until this point. In fact, pharmaceutical giants Pfizer and GlaxoSmithKline both invested heavily in resveratrol research, and had come to conflicting conclusions about, which in large part touched off the scientific stalemate that Sinclair’s recent findings have helped to resolve:
How resveratrol and similar compounds worked remained something of a mystery. Scientists believe it stimulates a sirtuin known as SIRT1 that breaks up certain proteins, helping them change cell behavior in ways that are beneficial to health.
“SIRT1 is like a Pac-Man that removes these proteins and tells other proteins to go out and repair the cell,” Sinclair said.
When SIRT1 was active, miraculous things seemed to happen.
What the next step will be for the use of resveratrol remains up in the air. However, given how fast biotech companies usually work to capitalize on new, exciting research like this, it stands to reason that many of the key players in Big Pharma will move to be first to trial new treatments, and first to market with a finished product.